Dyax Corp.

    [td_text_with_title custom_title=”Company description”]Dyax is a biopharmaceutical company focused on the development and commercialization of novel biotherapeutics for unmet medical needs. The Company is developing DX-2930, a fully human monoclonal antibody, for the prevention of HAE attacks. In March 2015, the Company reported positive safety, pharmacokinetic, biomarker and proof-of-concept efficacy results from its Phase 1b clinical trial of DX-2930 in HAE patients. Additionally, Dyax markets KALBITOR® (ecallantide) for the treatment of acute attacks of HAE in patients 12 years of age and older.

    Both DX-2930 and KALBITOR were identified using Dyax’s proprietary phage display technology. Dyax has broadly licensed this technology under its Licensing and Funded Research Portfolio (LFRP). The current portfolio includes one FDA approved product, Eli Lilly and Company’s CYRAMZA® (ramucirumab), for which Dyax receives royalties, and multiple product candidates in various stages of clinical development for which the Company is eligible to receive future milestones and royalties.[/td_text_with_title]

    Drugs

    Ofatumumab

    Ofatumumab is a novel, investigational, fully human monoclonal antibody that targets a membrane-proximal (close to the cell surface) small loop epitope (a portion of a molecule to which an antibody binds) on the CD20 molecule of B-cells.  This epitope is different from the binding sites targeted by other CD20 antibodies currently available.  The CD20 molecule [...]
    0 comments

    Daratumumab

    Daratumumab is a human CD38 monoclonal antibody with broad-spectrum killing activity. Daratumumab is in clinical development for multiple myeloma (MM). Daratumumab targets the CD38 molecule which is highly expressed on the surface of multiple myeloma cells. Daratumumab may also have potential in other cancers on which CD38 is expressed, including diffuse large B-cell lymphoma, chronic [...]
    0 comments
    [td_text_with_title custom_title=”Latest post”]
    185914

    Presentation of Castor study at ASCO 5th june 2016

    0 comments

    Did Marshall Wace loose more than 100 million DKK on Genmab?

    Marshall Wace LLP have tried several times over the last years to short Genmab and have failed miserably. The 4th of december 2015 they announced that they finally have reduced their short in the company –  after stubbornly have been entrenched in their position amidst an increase in share value of almost 50% in just 3 […]

    0 comments
    Genmab kommentar

    Genmab Q3 2015

    http://inrater.com/wp-content/uploads/2015/11/Genmab_q3.m4v
    0 comments

    Genmab – takeover eller uptake?

    Vi står overfor et nyt medicin eventyr i Danmark, på linie med Lundbecks Cipramil og Novo Nordisks Insulin præparater. Det lyder stort og det er det også, ikke mindst fordi Genmabs succes sker på det mest profitable segment indenfor medicinalprodukter, nemlig kræftbehandling. Genmab står således foran en veritabel forandring som virksomhed, hvor man – godt […]

    0 comments

    Hurtig rebound men mange muligheder stadigt

    Vi har fået en del danske kunder og jeg vil af og til bidrage på dansk med mit syn på mine stockpicks og markedet generelt. Vi fik præcis det rebound som vi spekulerede i for et par uger siden. Vi har i denne uge taget en position i en dansk bank, som handles under indre...

    Vores uafhængige analyser er tilgængelig mod betaling / This content is for Peter Hildebrandt Fundmanager Subscription and Premium - ALL fundmanagers members only.
    Log In Register
    0 comments

    Genmab Q2 & conference call – key takeaway

    In this and the coming quarters Genmab is focusing on its late stage assets as they progress toward an approval for Daratumumab and expansion of the label for Arzerra. The revenue and cost side of the company is as expected, there are no crazy things going around in the balancesheet. But there were some eyeopening information from...

    Vores uafhængige analyser er tilgængelig mod betaling / This content is for Peter Hildebrandt Fundmanager Subscription and Premium - ALL fundmanagers members only.
    Log In Register
    0 comments
    Genmab kommentar

    Genmab submits sBLA for Ofatumumab

    Company Announcement sBLA submitted to US FDA for ofatumumab as maintenance therapy in relapsed CLL by Novartis Submission based on data from interim results of Phase III PROLONG study Copenhagen, Denmark; July 22, 2015 — Genmab A/S (OMX: GEN) announced today that a supplemental Biologics License Application (sBLA) has been submitted to the U.S. Food and […]

    0 comments
    Genmab kommentar

    Genmab completes Rolling Submission for Daratumumab

    Company Announcement Submission of rolling BLA to US FDA for daratumumab in multiple myeloma completed by Janssen Biotech, Inc. Completion of submission triggers USD 15 million milestone payment to Genmab Copenhagen, Denmark; July 9, 2015 — Genmab A/S (OMX: GEN) announced its licensing partner Janssen Biotech, Inc. has completed the rolling submission of the Biologics License […]

    0 comments
    182141

    Rituximab, Obinutuzumab, and Ofatumumab in CLL

    This is a discussion of practioners of the advantages of known regiments in CLL. The basic conclusion is that Rituxiamab is the prevailing standard, with obinutuzumab as a potential newcomer with a diffenriated method of action. Ofatumumab is given more of a chance in a refrac setting.

    0 comments
    Genmab kommentar

    Early Access Treatment for Daratumumab

    Janssen has submitted a new Phase 4, early access treatment trial on Clinicaltrials. org the 15th June 2015.  The objective of this study is to provide early access to daratumumab treatment and collect additional safety data while the medication is not commercially available for subjects with multiple myeloma who have received at least 3 prior lines of […]

    0 comments
    Goldman Sachs

    Genmab – unfolding Daratumumab

    Genmab held a presentation at Goldman Sachs 9th june 2015 following ASCO and recent BLA filing for Daratumumab. It was a 34 minute long Q&A session where we got some more insights in details in manufacturing and how Genmab sees the future for Daratumumab. The US plays a big role in any biotech and pharma […]

    0 comments
    Gilead

    IND filing Zydelig in combo with Arzerra

    Gilead announces submission of a supplemental New Drug Application to use Zydelig® in combination with ofatumumab in previously treated patients with CLL Submission based on data presented at American Society of Clinical Oncology Meeting 2015 Copenhagen, Denmark; June 1, 2015 — Genmab A/S (OMX: GEN) announced today that Gilead has published that it has submitted […]

    0 comments
    Daratumumab target

    Daratumumab – Genmabs næste lægemiddel?

    Genmab kom tirsdag d. 3. februar efter lukketid med data på et vigtigt studie for Daratumumab. Længe ventet kan man måske ikke kalde det, fordi udviklingen er i kræftmedicinsammenhæng gået meget hurtigt, men i forhold til kursudviklingen har det været ventet med længsel. Igennem en periode på 2 år er interessen for Daratumumab i Multiple […]

    3 comments
    den næste genmab

    Den næste Genmab?

    Efter Genmab´s fantastiske kursudvikling de sidste 2-3 år, hvor aktien er steget omkring 18 gange fra bunden, så spørger mange private investorer sikkert sig selv, hvordan – hvis overhovedet – man kan finde den næste Genmab case. En advarsel er på sin plads her, for grundlæggende er den slags stockpicking ikke vejen frem til en sund formue. […]

    0 comments
    [/td_text_with_title]